Scholars@Duke
Joseph Junyong Park

Joseph Junyong Park

Clinical Faculty in the Department of Medicine
Medicine, Medical Oncology

Scholarly Works - Conferences

Clinical and genomic predictors of sipuleucel-T (sip-T) outcomes in men with metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · March 1, 2026 228Background: Survival outcomes with sip-T in mCRPC are variable, and mechanisms dri ... Full text Cite

SPOP mutations in veterans with metastatic castration-resistant prostate cancer (mCRPC) and the association with race and response to an androgen receptor pathway inhibitor (ARPI).

Conference Journal of Clinical Oncology · June 2025 e17082Background: Inactivating missense mutations in the tumor suppressor gene speckle-type pox virus and zinc finger protein ... Full text Cite

Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI).

Conference Journal of Clinical Oncology · June 1, 2025 e17085 Background: Inactivating missense mutations in the tumor suppressor gene speckle-type POZ (SPOP) increase the transcriptional activity of the androgen receptor (AR) and sensitivity to hormonal therapies in men with hormone sensitive prostate cancer. ... Full text Cite

Profiling of exceptional responders (ER) and non-responders (NR) to androgen receptor pathway inhibitors (ARPI) in men with metastatic hormone sensitive and castration resistant prostate cancer.

Conference Journal of Clinical Oncology · June 2025 e17107Background: In clinical practicea subset of patients treated with androgen deprivation therapy (ADT) plus an ARPI achie ... Full text Cite

Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).

Conference Journal of Clinical Oncology · June 1, 2023 4574 Background: MTAP loss of function alt in aUC has been associated with poor prognosis. MTAP is an enzyme involved in the adenine salvage pathway and deficiency of the protein leads to susceptibility to antifolate agents, e.g. ... Full text Cite

Biomarker-directed therapy in black and white men with metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · June 1, 2022 5013 Background: Black men have been underrepresented in large-scale molecular prostate cancer (PC) surveys, despite having higher PC incidence and mortality. Since molecular profiling to guide the use of targeted agents is incre ... Full text Cite

Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).

Conference Journal of Clinical Oncology · February 20, 2022 138 Background: AR alterations such as ligand binding domain mutations and amplification evolve under the selective pressure of testosterone suppression and AR targeted agents (ARTA) such as abiraterone or enzalutamide, but their ... Full text Cite

DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.

Conference Journal of Clinical Oncology · February 20, 2022 129 Background: Pathogenic HRR gene mutations may confer sensitivity to PARP inhibitors (PARPi) and/or platinum chemotherapy (chemo). While pts harboring mutations in BRCA1/2 appear to benefit from these DNA damaging therapeutics ... Full text Cite

Outcomes of patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs): Associations with age, race, sex and smoking history.

Conference Journal of Clinical Oncology · May 20, 2021 e16526 Background: ICIs have altered the therapeutic landscape in pts with aUC and new biomarkers are needed to better predict response and outcomes with ICIs. It is unclear whether demographics, such as race, age, sex and histor ... Full text Cite

Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.

Conference Journal of Clinical Oncology · May 20, 2021 4568 Background: Advanced sRCC is an aggressive disease with limited responsiveness to chemotherapy and VEGF-targeted therapies. Subgroup analyses from randomized trials showed improved outcomes with ICI, though sample sizes were ... Full text Cite

Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.

Conference Journal of Clinical Oncology · February 20, 2021 406 Background: Despite anatomical and biological differences, upper and lower tract UC (UTUC; LTUC) are usually managed similarly. Modern era clinical trial data comparing their outcomes with ICI are conflicting. We hypothesized ... Full text Cite

Phase Ib/II study of durvalumab and guadecitabine in advanced kidney cancer Big Ten Cancer Research Consortium BTCRC GU16-043.

Conference Journal of Clinical Oncology · February 20, 2021 328 Background: Anti-PD1/PDL1 immune checkpoint inhibition (CPI) is active in advanced clear cell RCC, but not all patients benefit. Preclinical studies with the combination of hypomethylating agents and CPI resulted in reversal ... Full text Cite

Association between prior radical surgery (RS) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).

Conference Journal of Clinical Oncology · February 20, 2021 444 Background: It is unclear whether prior RS of primary tumor is associated with response and outcomes with ICI in aUC. We hypothesized that such response and outcomes would not differ based on prior RS. Methods: We performed a ... Full text Cite

Heteroclitic peptide cancer vaccine counters MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms

Conference The Journal of Immunology · May 1, 2020 AbstractThe majority of JAK2WT myeloproliferative neoplasms (MPN) have disease-initiating frameshift mutations in calreticulin (CALR) resulting in a common novel C-terminal mutant fragment (CALRMUT), represe ... Full text Cite

Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.

Conference Journal of Clinical Oncology · February 1, 2017 353 Background: Stereotactic body radiation therapy (SBRT) is an emerging treatment option for unresectable pancreatic cancer, and may be more effective and less toxic than intensity modulated radiation therapy (IMRT). Methods: W ... Full text Cite